Opinion|Videos|January 28, 2025
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Author(s)Max Kates, MD
Max Kates, MD, discusses how the ability to deliver newer treatments in local urology clinics rather than specialized centers reduces patient travel burden and improves access to care, while suggesting that increased education about safety profiles and implementation protocols could encourage broader adoption among health care providers.
Advertisement
Episodes in this series
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss overall burden on patients, systemic side effects, and travel to specialized centers
- What strategies would you recommend to encourage more HCPs to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
